• Elevated lipoproteinp(a) is an independent and causal risk factor for atherothrombotic diseases.
Introduction
Elevated plasma concentrations of lipoprotein(a) (Lp(a)) have been identified as a causal risk factor for atherothrombotic diseases such as coronary heart disease (CHD) [1] . This complex lipoprotein consists of an LDL moiety covalently linked to the unique glycoprotein apolipoprotein(a) (apo(a)) by a single disulfide linkage [2] . apo(a) is homologous to the plasma zymogen plasminogen, and has been shown to have similar Lys-dependent binding to substrates such as fibrin [3] . apo(a) contains 10 distinct copies of a plasminogen-like KIV domain, each present in a single copy except for KIV 2 [4] . These domains are followed by plasminogen-like sequences resembling KV and an inactive protease domain [4] . The KIV 2 domain of apo(a) can be present from < 3 to > 30 copies, giving rise to the immense isoform size heterogeneity found within the population [5] . Recent Mendelian randomization studies have determined that the genetic variation in LPA, the gene encoding apo(a), is a causal risk factor for CHD [6] . The size of LPA, reflecting the number of KIV 2 repeats encoded by the gene, is inversely correlated with plasma Lp(a) levels and the risk of myocardial infarction [7] . The influence of LPA on CHD risk has identified elevated Lp(a) as the single strongest genetic risk factor for CHD [6] .
Several genetic studies have identified an association between a single-nucleotide polymorphism (SNP) within LPA and an increased risk for CHD [1] . The rs3798220 SNP results in an Ile?Met substitution at position 4399 (within the inactive protease domain) of apo(a) [8] . This variant of LPA has been correlated with a smaller number of KIV 2 repeats, and is associated with elevated Lp(a) levels and a greater risk of cardiovascular disease [1, 8, 9] . The minor allele frequency is highest in Hispanics (42.4%), lowest in African Americans (1.5%), and intermediate in Caucasians (4.3%) [10] . In a randomized trial of low-dose aspirin therapy in women, it was observed that rs3798220 carriers had significantly higher Lp(a) levels than non-carriers and a doubled risk for cardiovascular disease [11] . Interestingly, carriers had a greater than two-fold decrease in cardiovascular risk in response to low-dose aspirin, an outcome not seen in non-carriers; the increment in risk was independent of changes in Lp(a) plasma levels. This may suggest that the Met-containing variant of apo(a) may confer a novel or heightened pathogenic role for Lp(a) in CHD. However, it remains unclear whether Lp(a) containing Met at position 4399 is inherently more pathogenic, or whether this coding variation is linked with some other genetic factor that directly causes disease. In a recent in vitro study of human plasma samples, elevated Lp(a) levels were correlated with reduced clot permeability and increased clot lysis times [12] . Furthermore, plasma from carriers of the polymorphism showed ethnicity-dependent variations in plasma clot permeability and lysis times, with Caucasians having less permeable clots and a lower rate of lysis than other ethnic groups. In another study, subjects carrying this polymorphism with elevated Lp(a) levels also had increased levels of oxidized phospholipids on Lp(a) [13] . In the current study, we used a recombinant variant of apo(a) containing the I4399M substitution to directly assess the impact of this variation on coagulation, fibrinolysis, and fibrin clot structure.
Experimental procedures
Purification of recombinant apo(a) and plasma-derived Lp(a)
Plasmids encoding a 17-kringle-containing form of recombinant apo(a) [17K r-apo(a)], as well as KIV 10 -P, were constructed and transfected into human embryonic kidney 293 cells as previously described [3, 14, 15] . 17KI4399M and KIV 10 -P I4399M variants corresponding to the rs3798220 SNP were generated by site-directed mutagenesis with the QuikChange II-XL Site-Directed Mutagenesis Kit (Agilent Technologies, Mississauga, ON Canada). All r-apo(a) species were purified from the conditioned medium of stably expressing cell lines by LysSepharose (GE Healthcare, Mississauga, ON Canada) affinity chromatography as previously reported [14] .
Lp(a) was purified from the plasma of a healthy volunteer with an apo(a) isoform containing 16 KIV domains by use of a previously described protocol [16] .
Human subjects
Subjects were either healthy volunteers or were from a tertiary referral lipid clinic (Table 1) . There were no specific inclusion or exclusion criteria. Subjects were free of symptomatic cardiovascular disease at the time of sample collection. Informed consent was obtained from subjects prior to DNA collection and analysis with a protocol approved by the University of Western Ontario Ethics Review Board (#07920E). Blood was collected and plasma and genomic DNA were prepared as previously described [17] . The rs3798220 variant of LPA was genotyped with a validated TaqMan assay on a ViiA7 Real-Time PCR System and automated software (Applied Biosystems, ThermoFisher Scientific, Burlington, ON, Canada), or by direct sequencing of PCR products, at the London Regional Genomics Centre. Lp(a) isoform size was determined in plasma samples by SDS-agarose gel electrophoresis [18] , with an anti-apo(a) antibody raised against r-apo(a). apo(a) isoform sizes were determined by use of a ladder of recombinant apo(a) isoform standards. Lp(a) plasma levels were determined withy the Macra Lp(a) ELISA (Mercodia, Uppsala, Sweden) according to the manufacturer's protocol.
In vitro coagulation and fibrinolysis assays
Clot lysis assays were performed in similar manner as previously published, with some modifications [19] . Lipoprotein-deficient plasma (LPDP), prepared from a single, healthy volunteer, was diluted 1 : 1 with 20 mM Tris (pH 7.4), 150 mM NaCl, and 0.01% [v/v] Tween-20, and supplemented with three different concentrations of 17K r-apo(a) (wild-type or I4399M variant; 0.5, 1.0 and 1.5 lM). The reaction mixture was added to wells containing small, separated aliquots of CaCl 2 , human thrombin (Haematological Technologies, Essex Junction, VT USA) and tissue-type plasminogen activator (t-PA) (Alteplase, CathFlo; Roche, Mississauga, ON, Canada) at final concentrations of 10 mM, 1 U mL À1 , and 3 nM, respectively.
Lysis of the resulting clots was monitored by measurement of absorbance at 405 nm in a plate-reading spectrophotometer at 37°C. Plasma coagulation assays were performed in similar manner to the clot lysis assay, except that coagulation was initiated with 20 mM CaCl 2 and 1 U mL À1 thrombin, and t-PA was omitted.
Plasminogen activation on a fibrin surface
Plasminogen activation on the surface of a fibrin clot was performed exactly as previously published [14] .
Measurement of plasma clot permeability
Fibrin clot permeability was determined with a pressuredriven system, used exactly as previously described [20] , with the following modifications. The clotting mixture volume was 120 lL (versus 100 lL), and the clots were held in clear glass tubes (cut from the tip end of a 1-mL graduated pipette) rather than plastic pipette tips with roughened interiors. The 1.5-h washing step was reduced to 1 h, and the volumes flowing through the fibrin gels were measured over a period of 1 h (versus 2 h). A permeation coefficient (K s ) was calculated as previously described [20] .
Confocal and scanning electron microscopy of clots Clots were formed in a similar manner to that used for clot permeability (see above), except for supplementation of the plasma prior to clotting with 0.3 mg mL À1 Alexa
Fluor 568-labeled (Invitrogen kit, ThermoFisher Scientific, Burlington, ON, Canada) fibrinogen (Calbiochem, Millipore, Etobicoke, ON, Canada). The clots were allowed to mature for 3 h in a moist chamber at room temperature, and then washed with buffer to remove excess label. The resulting fluorescent clots were imaged on an Olympus FV1000 confocal microscope (Olympus, Toronto, ON Canada). Images were analyzed for fiber density by the use of IMAGEJ with a custom-designed plugin [20] . Clots for scanning electron microscopy were prepared and subjected to permeation as described above, and this was followed by fixation for 30 
Molecular dynamics (MD) simulations and protease domain modeling
MOLECULAR OPERATING ENVIRONMENT (MOE) software was used for model preparation, energy minimizations, and assessment of the generated trajectories. The MD simulations were performed with NAMD [21] . All chemical models were derived from a previously published model of the apo(a) protease domain [22] . Water molecules present in the crystallographic structure were deleted. Hydrogen atoms and protons were then added to the model by use of the default method in MOE, with water molecules then being added (both throughout the protein and extending outwards from the edge of the protein to form a 6-A layer of water molecules) by use of the TIP3P water model [23] . The resulting solvated model was then minimized with the AMBER:12EHT force field until the rootmean-square gradient of the total energy was < 0.05 kcal mol À1 A À1 [24] . For all MD simulations, the AMBER12:EHT force field was used, as was the default velocity Verlet integration method to obtain the trajectories. The solvated systems were first equilibrated for 0.15 ns at 150 K, and the subsequent production MD simulations were run for 4.90 ns with a time step of 2 fs.
Mass spectrometry
Fifteen micrograms of either KIV 10 -P or KIV 10 -P/ I4399M protein was reduced with 16 mM dithiothreitol and reacted with 100 mM iodoacetamide (Sigma-Aldrich, Oakville, ON, Canada) for 60 min in the dark at room temperature with shaking. Samples were then subjected to a buffer exchange with ice-cold trichloroacetic acid (15% v/v), and this was followed by 20 min of incubation at 4°C. After centrifugation (10 000 9 g; 5 mins), three acetone washes of the pellet were performed. The pellet was resuspended in 4 9 reducing sample buffer. Samples were then subjected to SDS-PAGE; after staining, protein bands were excised and subjected to16 h of in-gel tryptic digestion with a ratio of~80 : 1 apo(a)/Trypsin Gold (Promega, Madison, WI, USA) [25] . Tryptic peptides were then extracted, spotted in a 1 : 1 ratio with a-cyano-4-hydroxycinnamic acid, and subjected to matrix-assisted laser desorption ionization-time-of-flight (MALDI-TOF) mass spectrometry with a Waters SYNAPT G2-Si instrument. The resulting spectra were analyzed with MASSLYNX (Waters, Mississauga, ON, Canada).
Pulse-chase secretion assay
HepG2 cells were transiently transfected with expression plasmids encoding 17K r-apo(a) with or without the I4399M SNP [15] . Cells were then starved for 1 h with Met-free and Cys-free Dulbecco's modified Eagle's medium without serum, pulse-labeled for 1 h in the same medium containing 200 lCi mL À1 [
35 S]Met, and chased in complete medium. Media and lysates were harvested at specific times from washed cells by the use of cold lysis buffer (100 mM Tris, pH 8.0, 100 mM NaCl, 10 mM EDTA, 1% [v/v] Triton X-100, 0.1% [w/v] SDS, 100 mM e-aminocaproic acid) containing protease inhibitors. Following brief centrifugation (10 000 9 g; 1 min), samples were precleared by incubation with gelatin-agarose (Sigma-Aldrich) for 2 h at 4°C, and this was followed by immunoprecipitation and resolution by reducing SDS-PAGE as previously described [26] . The gels were dried and exposed to a phosphor screen (Fujifilm, Mississauga, ON, Canada), which was imaged with a Molecular Imager FX (Bio-Rad, Mississauga, ON, Canada). Protein secretion rates were determined by densitometric analysis with ALPHA VIEW (AlphaInnotech, ThermoFisher Scientific, Burlington, ON, Canada), and presented as a percentage of the intensity of the maximum-intensity wild-type 17K sample.
Statistical methods
Comparisons between samples were performed by oneway ANOVA with a Tukey post hoc analysis by the use of SPSS, Version 22.0 (SPSS, Armonk, NY, USA). Statistical significance was assumed at P < 0.05.
Results

The effect of I4399M apo(a) on clot formation
In preliminary experiments, we noticed that addition of 17K I4399M apo(a) to a solution containing physiologic concentrations of fibrinogen resulted in a cloudy solution, whereas addition of 17K apo(a) had no such effect. We determined that this phenomenon was caused by the 17K I4399M apo(a)-mediated precipitation of fibrinogen, which did not occur with 17K apo(a) (Fig. 1) . This finding prompted us to investigate the effects of 17K I4399M apo(a) on plasma clot formation and lysis.
We titrated 17K and 17K I4399M apo(a) into LPDP, and initiated coagulation by the addition of CaCl 2 and thrombin. Addition of wild-type 17K apo(a) had no effect on the maximum turbidity (i.e. change in absorbance) observed upon clot formation ( Fig. 2A) . However, addition of 17K I4399M apo(a) resulted in a significant dosedependent increase (up to 33%) in the maximum turbidity of the clots ( Fig. 2A; Fig. S1 ). Increasing concentrations of 17K apo(a) resulted in a dose-dependent decrease in the time to 50% clotting (up to 34%) as compared with clots formed in the absence of apo(a) ( Fig. 2B; Fig. S1 ). 17K I4399M apo(a) had an apparently greater effect, with additional decreases in time to 50% clotting as compared with 17K apo(a), although these differences did not reach statistical significance (Fig. 2B ).
I4399M apo(a) more potently inhibits fibrinolysis
We next compared the ability of 17K and 17K I4399M apo(a) to inhibit fibrinolysis, by using a similar in vitro assay containing LPDP but with the addition of t-PA. As compared with control samples lacking apo(a), clot lysis times were significantly increased in the presence of 17K apo(a), which extended lysis times by up to 9.5-fold were incubated for 10 min at room temperature alone or in combination. In the case of turbid samples, insoluble material was collected by centrifugation. Supernatant (S) and pellet (P) (when applicable) samples were subjected to SDS-PAGE analysis under reducing conditions, followed by Imperial staining to visualize protein bands. The migration positions of molecular weight markers and the fibrinogen Aa, Bb and c chains are indicated.
( Fig. 3A; Fig. S2 ). 17K I4399M apo(a) resulted in significant additional increases in clot lysis times as compared with 17K apo(a) ( Fig. 3A; Fig. S2 ). We then evaluated whether differences between 17K and 17K I4399M apo(a) in inhibition of clot lysis might be related to differences in their ability to inhibit plasminogen activation. To do this, we measured the effect of these variants on the activation of a fluorescently labeled plasminogen variant that is catalytically inactive upon cleavage by t-PA (Fig. 3B) . Both apo(a) variants yielded a dose-dependent decrease in plasminogen activation (between~25% and~45%), but there was no significant difference between 17K and 17K I4399M apo(a) (Fig. 3B) .
I4399M apo(a) alters fibrin clot structure
Fibrin clots were generated with purified components supplemented with 17K or 17K I4399M apo(a). After glutaraldehyde fixation and extensive washes, fibrin clots were subjected to low-vacuum scanning electron microscopy to assess clot structure. Figure 4A shows representative secondary electron images taken at 9 30 000 magnification. Whereas there was no difference in the width of fibrin fibers between clots lacking apo(a) and those containing 17K apo(a), clots containing 17K I4399M apo(a) had fiber widths that were significantly greater (Fig. 4B ).
Clots formed from the plasma of subjects homozygous for the rs3798220 SNP are structurally distinct
Clots formed in plasma from a total of four subjects with either high (> 30 mg dL
À1
) or low (< 10 mg dL À1 ) plasma Lp(a) levels, and homozygous for either the Metencoding or Ile-encoding LPA allele, were assessed for fibrin fiber density, plasma clot permeability, and average fibrin fiber width. Subjects of either genotype were matched for similar plasma Lp(a) level and apo(a) isoform size (Table 1 ). Figure 5A shows confocal microscopy images of representative plasma clots from each subject; clots were supplemented with fluorescently labeled fibrinogen to visualize fibrin fibers. Fiber density was similar in clots formed from the plasma of subjects with low Lp(a) levels and of either genotype (Fig. 5B ). In the case of individuals with higher Lp(a) levels, fiber density was significantly greater for the Ile/Ile homozygote than for the Met/Met homozygote (Fig. 5B) , although the latter was not significantly different from either subject with low Lp(a) levels.
Permeability of clots made from the plasma of each subject was assessed (Fig. 5C ). There was a significant decrease of 30% in the permeation coefficient (an index of permeability) of clots formed from the plasma of subjects with elevated plasma Lp(a) levels as compared with those with low plasma Lp(a) levels, irrespective of the genotype of the subject (Fig. 5C ). Plasma clots from each subject were also subjected to fixation and scanning electron microscopy imaging (Fig. 5D) , followed by determination of fibrin fiber width (Fig. 5E ). Fiber width was significantly greater for subjects with high Lp(a) levels; moreover, the Met/Met homozygotes had greater fiber width than Ile/Ile homozygotes for both low and high Lp (a) levels.
Modeling of the apo(a) protease domain containing the I4399M substitution suggests structural differences from wild-type apo(a)
With a model for the protease domain of apo(a) [22] , average occupancy images were taken for a native apo(a) protease domain and a simulation incorporating an induced I4399M substitution. Figure 6A shows a comparison between the simulated domains. The first coordination sphere (with respect to the Ile/Met residue) suggests that the replacement of the Ile with the structurally distinct, but still non-polar, Met induces a conformational change in the local environment of this amino acid. In the native structure, Ile4399 is shielded from the bulk solvent by the adjacent Arg4420. When Met is in the 4399 position, however, the Arg4420 and Met4399 conform to a status whereby the Met is exposed to the solvent, and is no longer guarded by the neighboring Arg. As shown in Fig. 6B , a root-meansquare deviation analysis of the distance between the dcarbon on Ile, or the sulfur on the alternative Met, with the guanidine nitrogen on the adjacent Arg was explored to examine the relationship between these moieties. The 5-ns simulation suggested that the Met has a shorter average distance to the Arg of 3.39 AE 0.03 A, implying that the newly exposed Met4399 may be in a more coordinated state. Analysis of the Ile showed a greater and much more erratic average distance of 4.37 AE 0.12 A.
Identification of an oxidized Met in I4399M apo(a) KIV 10 -P and KIV 10 -P I4399M apo(a) were generated to assess the presence of oxidative modifications in the protease-like domain of apo(a) by the use of mass spectrometry. The smaller size of these variants was expected to yield more easily interpreted spectra. MALDI-TOF mass spectrometry of KIV 10 -P tryptic peptides identified a peptide, VILGAHQEVNLESHVQEIEVSR, which includes Ile4399, at the theoretical mass/charge ratio (m/z) of 2487.3 (data not shown). This indicates that this peptide is unmodified and present in its native form. Analysis of the corresponding peptide from the Met4399 variant was expected to be present at m/z = 2505.2 (Fig. 6C) , but a peptide of this mass was not detected (Fig. 6E) . Instead, a peptide with an increased m/z of 2521.2, corresponding The number of fibrin fibers per 100 lm 2 area was determined with IMAGEJ software. The data represent the means AE standard deviations (SDs) from analysis of four images each from two independent clots from each subject. *P < 0.05 as compared with subjects of the same genotype with low Lp(a) levels. (C) Clots prepared from the subjects described in (A) were subjected to a pressure-driven clot permeation assay to determine permeation coefficients (K s ). The data represent the means AE SDs from analysis of four clots from each subject. *P < 0.05 as compared with subjects of the same genotype with low Lp(a) levels. (D) Plasma clots prepared as in (C) were fixed and subjected to low-vacuum scanning electron microscopy. Representative images, taken at 9 30 000 magnification, are shown. (E) Fibers from the clots shown in (D) were assessed for average fiber width. Fiber widths were calculated with IMAGEJ, with a minimum of 30 fibers being measured on at least four images from two independent clots for each subject; means AE SDs are shown. *P < 0.05 versus subjects with different Lp(a) levels but the same genotype; ‡P < 0.05 versus subjects of the same genotype but with different Lp(a) levels.
to the presence of an oxidized Met in the peptide (Fig. 6D), was detected (Fig. 6E) .
Effect of the I4399M polymorphism on apo(a) secretion kinetics
Given the association of rs3798220 with elevated plasma Lp(a) levels, we also took advantage of our recombinant expression system to directly assess whether the Ile?Met substitution increases the rate of apo(a) biosynthesis. Using a pulse chase secretion assay in HepG2 cells, we found no difference in the rate of secretion of the Met variant and that of the Ile variant (Fig. 7) .
Discussion
We have directly examined the effects of the Ile?Met substitution encoded by rs3798220 on the pathogenic potential of Lp(a) by expressing and functionally characterizing a recombinant form of the variant, in the context of a physiologically relevant 17K isoform. The focus of our work has been on the effect of this mutation on coagulation, fibrinolysis, and fibrin clot structure. We found that the I4399M variant accelerated the coagulation of plasma clots in vitro, increased their maximum turbidity, and inhibited their lysis to a greater extent than the Ile (wild-type) variant. These effects were associated with an effect of the I4399M variant on the structure of fibrin, yielding clots with thicker fibrils. Our MD simulations of the effect of the Ile?Met substitution on the structure of the apo(a) protease domain and our subsequent discovery that the Met can be oxidized constitute a plausible basis for these observations.
It has been previously shown that Lp(a)/apo(a) can inhibit the reactions of fibrinolysis both in vitro and in vivo [3, 14, [27] [28] [29] . More recently, a report that apo(a) transgenic mice on a Plg À/À background had increased thrombotic potential when exposed to vascular injury led to an alternative model for the effects of apo(a) on thrombolysis, possibly involving changes in clot structure [30] . Indeed, elevated Lp(a) levels have been previously associated with altered fibrin clot structure, reduced permeability of fibrin clots and prolonged lysis times [31, 32] . Furthermore, human plasma from Caucasian patients carrying the rs3798220 SNP showed increased clot lysis times and decreased clot permeability as compared with that from Caucasian patients who were not carriers [12] . The I4399M variant specifically increased the maximum turbidity of the plasma clots in vitro, implying an effect on fibrin structure. Increased turbidity of a clot is indicative of thicker fibrin fibers, and is generally associated with attenuation of prothrombin activation or thrombin activity [33, 34] , although such an effect would not be occurring in our purified system. Thinner fibers, which yield lower turbidity, are more resistant to lysis than thick fibers [33, 35] . In contrast, we found that the I4399M variant results in higher turbidity and thicker fibers, and we speculate that this aberrant fibrin structure is uniquely resistant to lysis. Indeed, we found that clots containing the I4399M variant are more resistant to lysis than those containing wild-type apo(a), even though the two forms of apo(a) inhibited plasminogen activation to an equal extent.
We also studied clot structure and permeability by using, for the first time, plasma from individuals homozygous for the Met allele. Unlike what previous studies [12] have predicted, we found no difference in clot permeability between Ile/Ile and Met/Met subjects with similar Lp (a) levels, although the subjects with higher Lp(a) levels did, as expected, have lower clot permeability. The rs3798220 genotype did affect plasma clot fiber density, and amplified the ability of elevated Lp(a) levels to promote thicker fibrils. The latter finding agrees with what we observed in a purified system using r-apo(a). Given that our findings support the idea that both Lp(a) levels and rs3798220 influence fibrin clot structure, and hence the coagulability of plasma and its susceptibility to lysis, it is possible that the properties of the variant Lp(a) contribute to the increased risk of vascular disease in rs3798220 carriers through an effect on clot structure. Our MD simulations provide a possible structural and biochemical rationale for the effects of the Ile?Met substitution. Our analyses predict that introducing Met into the 4399 position will result in a change in the orientation of the nearby Arg4420 such that the Met can shift outwards into a more exposed conformation, effectively altering the surface of the protease domain in this variant. Moreover, larger fluctuations in the distance between Ile and Arg than in the distance between Met and Arg suggest that the Arg may stabilize the Met in its more solvent-exposed conformation. Indeed, we found strong evidence, through mass spectrometric analysis of recombinant apo(a), that Met4399 is oxidized.
Methionine sulfoxide moieties have been implicated in the dysfunction of several other plasma proteins, such as ApoA-I and fibronectin [36, 37] . The oxidation of Met on fibronectin was found to profoundly alter its ability to bind collagen, despite there being only a small conformational change of the protein. Given that Lys-independent fibrinogen binding sites have been identified among the KV and protease domains of apo(a) [38, 39] , it is tempting to speculate that the presence of the Met resulting from the rs3798220 SNP may influence the binding of the variant apo(a) to fibrin, altering the clot structure and potentially augmenting the pathogenic effects of Lp(a) thrombosis and fibrinolysis. It is also conceivable that the oxidation of the Met variant could alter binding of apo(a)/Lp(a) to additional substrates, potentially in ways that promote atherosclerosis. In vivo, Met oxidation can be mediated by hypochlorous acid produced by myeloperoxidase, an enzyme that is released in abundance in atherosclerotic lesions by macrophages [40] ; the Met variant may therefore be susceptible to oxidation within the plaque milieu.
It is possible that the association of the rs3798220 polymorphism and elevated Lp(a) levels is not attributable to the SNP directly, but to the correlation of this variant with smaller apo(a) isoforms, which are more readily secreted [13] . We found, however, that the I4399M substitution does not impact on apo(a) secretion. Interestingly, it has been reported that the rs3798220 SNP is associated with increased Lp(a) levels in Caucasians, but not in nonCaucasians [10, 12] , which also argues against a direct functional impact of the SNP on plasma Lp(a) concentrations. It cannot be excluded that the I4399M substitution affects other processes that impact on plasma Lp(a) levels, such as Lp(a) assembly or catabolism.
In conclusion, our findings strongly suggest that the Met4399 variant has greater prothrombotic/antifibrinolytic potential, at least in part through deleterious effects on fibrin structure. Our findings should prompt additional genetic and epidemiologic studies to evaluate the impact of this polymorphism on cardiovascular outcomes. 126076), Heart and Stroke Foundation of Canada (G-13-0003091), and Natural Sciences and Engineering Research Council of Canada (RGPIN/5006-2015).
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